Table 3.
Toxicity of CAR-T treatment.
| Event | |
|---|---|
| CRS, any grade, n (%) | 133 (92%) |
| Grade ≥3 | 7 (5%) |
| Median time to onset (min–max) | 2 days (0–9) |
| Median duration | 5 days (1–7) |
| ICANS, any grade, n (%) | 90 (62%) |
| Grade ≥3 | 32 (22%) |
| Median time to onset (min–max) | 6 days (1–28) |
| Median duration | 5 days (1–28) |
| Tocilizumab use, n (%) | 103 (71%) |
| Anakinra use, n (%) | 3 (2%) |
| Steroids use, n (%) | 93 (64%) |
| Any grade and any type infections, n (%) | |
| Month <1 | 38 (26%) |
| Months 1–12 | 61 (43%) |
| Months >12 | 33 (43%) |
| Thrombocytopenia at Month 3, n (%) | 59 (45%) |
| Grade ≥3 | 19 (15%) |
| Missing | 5 (4%) |
| Anemia at Month 3, n (%) | 95 (73%) |
| Grade ≥3 | 9 (7%) |
| Missing | 5 (4%) |
| Neutropenia at Month 3, n (%) | 62 (47%) |
| Grade ≥3 | 45 (34%) |
| Missing | 6 (5%) |
| CD4 < 0.2 × 109/L at 1 year, n (%) | 37 (49%) |
| Missing | 27 (36%) |
| CD8 < 0.2 × 109/L at 1 year, n (%) | 25 (33%) |
| Missing | 27 (36%) |
| B-cell aplasia (B-cells/lymphocytes < 0.5%) at 1 year, n (%) | 40 (53%) |
| Missing | 26 (34%) |
| Hypogammaglobulinemia (IgG < 6 g/L) at 1 year, n (%) | 52 (68%) |
| Missing | 17 (22%) |
| Median hospital admission duration (min–max) | 14 days (7–78) |
| Patients that died during admission, n (%) | 4 (3%) |
| ICU admission, n (%) | 20 (14%) |
| Median ICU admission duration (min–max) | 3 days (1–19) |
| ER visits and readmissions < Month 1, n (%) | 18 (12%) |
| Readmission for CAR-T related toxicity, n | 7 (neurotoxicity 6, infection 1) |
| ER visits and readmissions between Month 1–3, n (%) | 26 (18%) |
| Readmission for CAR-T related toxicity, n | 19 (neurotoxicity 2, infection 17) |
Abbreviations: CRS, cytokine release syndrome, ER: emergency room, ICANS: immune effector-cell associated neurotoxicity syndrome, ICU: intensive care unit.